Total Payments
$15,921
2024 Payments
$2,094
Companies
21
Transactions
871
Medicare Patients
1,115
Medicare Billing
$391,388
Payment Breakdown by Category
Food & Beverage$15,790 (99.2%)
Education$131.57 (0.8%)
Other$0.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $15,790 | 851 | 99.2% |
| Education | $131.57 | 20 | 0.8% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Sunovion Pharmaceuticals Inc. | $3,008 | 168 | $0 (2022) |
| Otsuka America Pharmaceutical, Inc. | $2,802 | 129 | $0 (2024) |
| Lundbeck LLC | $1,989 | 149 | $0 (2024) |
| ABBVIE INC. | $1,233 | 72 | $0 (2024) |
| Allergan, Inc. | $1,193 | 54 | $0 (2021) |
| Janssen Pharmaceuticals, Inc | $1,058 | 42 | $0 (2024) |
| Neurocrine Biosciences, Inc. | $933.28 | 39 | $0 (2024) |
| Alkermes, Inc. | $910.65 | 45 | $0 (2024) |
| ITI, Inc. | $621.66 | 41 | $0 (2023) |
| Teva Pharmaceuticals USA, Inc. | $550.74 | 41 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $2,094 | 111 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) ($466.85) |
| 2023 | $2,272 | 133 | Otsuka America Pharmaceutical, Inc. ($359.93) |
| 2022 | $1,988 | 113 | Sunovion Pharmaceuticals Inc. ($620.40) |
| 2021 | $2,070 | 110 | AbbVie Inc. ($556.01) |
| 2020 | $1,543 | 83 | Allergan, Inc. ($469.55) |
| 2019 | $2,241 | 123 | Otsuka America Pharmaceutical, Inc. ($686.88) |
| 2018 | $1,925 | 115 | Sunovion Pharmaceuticals Inc. ($699.17) |
| 2017 | $1,788 | 83 | Sunovion Pharmaceuticals Inc. ($747.94) |
All Payment Transactions
871 individual payment records from CMS Open Payments — Page 1 of 35
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/19/2024 | Neurocrine Biosciences, Inc. | INGREZZA (Drug) | Food and Beverage | In-kind items and services | $35.28 | General |
| Category: Neuropsychiatry | ||||||
| 12/18/2024 | Neurocrine Biosciences, Inc. | INGREZZA (Drug) | Food and Beverage | In-kind items and services | $10.58 | General |
| Category: Neuropsychiatry | ||||||
| 12/18/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $7.76 | General |
| Category: NEUROSCIENCE | ||||||
| 12/17/2024 | E.R. Squibb & Sons, L.L.C. | COBENFY (Drug) | Food and Beverage | Cash or cash equivalent | $17.86 | General |
| Category: Psychiatry/Psychology | ||||||
| 12/16/2024 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | CAPLYTA (Drug) | Food and Beverage | In-kind items and services | $14.81 | General |
| Category: PSYCHIATRY | ||||||
| 12/11/2024 | Vanda Pharmaceuticals Inc. | FANAPT (Drug) | Food and Beverage | In-kind items and services | $13.25 | General |
| Category: SCHIZOPHRENIA | ||||||
| 12/10/2024 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | CAPLYTA (Drug) | Food and Beverage | In-kind items and services | $34.73 | General |
| Category: PSYCHIATRY | ||||||
| 12/10/2024 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | CAPLYTA (Drug) | Food and Beverage | In-kind items and services | $16.50 | General |
| Category: PSYCHIATRY | ||||||
| 12/10/2024 | Lundbeck LLC | ABILIFY ASIMTUFII (Drug) | Food and Beverage | Cash or cash equivalent | $16.02 | General |
| Category: PSYCHIATRY | ||||||
| 12/10/2024 | Lundbeck LLC | ABILIFY ASIMTUFII (Drug) | Food and Beverage | Cash or cash equivalent | $8.49 | General |
| Category: PSYCHIATRY | ||||||
| 12/05/2024 | Otsuka America Pharmaceutical, Inc. | ABILIFY ASIMTUFII (Drug), ABILIFY MAINTENA | Food and Beverage | In-kind items and services | $25.22 | General |
| Category: PSYCHIATRY | ||||||
| 12/05/2024 | Otsuka America Pharmaceutical, Inc. | ABILIFY ASIMTUFII (Drug), ABILIFY MAINTENA | Food and Beverage | In-kind items and services | $2.34 | General |
| Category: PSYCHIATRY | ||||||
| 12/03/2024 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | CAPLYTA (Drug) | Food and Beverage | In-kind items and services | $4.74 | General |
| Category: PSYCHIATRY | ||||||
| 11/26/2024 | Alkermes, Inc. | ARISTADA (Drug), ARISTADA, ARISTADA | Food and Beverage | In-kind items and services | $15.92 | General |
| Category: CNS | ||||||
| 11/21/2024 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | CAPLYTA (Drug) | Food and Beverage | In-kind items and services | $17.03 | General |
| Category: PSYCHIATRY | ||||||
| 11/21/2024 | Otsuka America Pharmaceutical, Inc. | ABILIFY ASIMTUFII (Drug), ABILIFY MAINTENA | Food and Beverage | In-kind items and services | $14.26 | General |
| Category: PSYCHIATRY | ||||||
| 11/20/2024 | Neurocrine Biosciences, Inc. | INGREZZA (Drug) | Food and Beverage | In-kind items and services | $31.88 | General |
| Category: Neuropsychiatry | ||||||
| 11/12/2024 | Alkermes, Inc. | ARISTADA (Drug), ARISTADA, ARISTADA | Food and Beverage | In-kind items and services | $20.99 | General |
| Category: CNS | ||||||
| 11/07/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $22.51 | General |
| Category: NEUROSCIENCE | ||||||
| 11/07/2024 | Neurocrine Biosciences, Inc. | INGREZZA (Drug) | Food and Beverage | In-kind items and services | $8.31 | General |
| Category: Neuropsychiatry | ||||||
| 11/06/2024 | Lundbeck LLC | ABILIFY ASIMTUFII (Drug) | Food and Beverage | Cash or cash equivalent | $13.24 | General |
| Category: PSYCHIATRY | ||||||
| 11/01/2024 | Neurocrine Biosciences, Inc. | INGREZZA (Drug) | Food and Beverage | In-kind items and services | $119.85 | General |
| Category: Neuropsychiatry | ||||||
| 10/30/2024 | Neurocrine Biosciences, Inc. | INGREZZA (Drug) | Food and Beverage | In-kind items and services | $30.80 | General |
| Category: Neuropsychiatry | ||||||
| 10/30/2024 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | CAPLYTA (Drug) | Food and Beverage | In-kind items and services | $15.03 | General |
| Category: PSYCHIATRY | ||||||
| 10/24/2024 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | CAPLYTA (Drug) | Food and Beverage | In-kind items and services | $9.77 | General |
| Category: PSYCHIATRY | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 4 | 157 | 1,142 | $171,980 | $69,781 |
| 2022 | 3 | 235 | 1,344 | $200,240 | $83,054 |
| 2021 | 7 | 336 | 1,839 | $269,620 | $120,823 |
| 2020 | 7 | 387 | 1,911 | $270,960 | $117,730 |
Total Patients
1,115
Total Services
6,236
Medicare Billing
$391,388
Procedure Codes
21
All Medicare Procedures & Services
21 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 90833 | Psychotherapy with evaluation and management visit, 30 minutes | Office | 2023 | 62 | 558 | $82,180 | $29,735 | 36.2% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 53 | 457 | $65,820 | $27,016 | 41.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 31 | 110 | $21,100 | $11,577 | 54.9% |
| 90834 | Psychotherapy, 45 minutes | Office | 2023 | 11 | 17 | $2,880 | $1,453 | 50.5% |
| 90833 | Psychotherapy with evaluation and management visit, 30 minutes | Office | 2022 | 90 | 672 | $97,200 | $37,106 | 38.2% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 80 | 503 | $70,620 | $29,495 | 41.8% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 65 | 169 | $32,420 | $16,452 | 50.7% |
| 90833 | Psychotherapy performed with evaluation and management visit, 30 minutes | Office | 2021 | 101 | 799 | $115,440 | $44,761 | 38.8% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 90 | 566 | $79,800 | $37,292 | 46.7% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 80 | 237 | $43,790 | $22,849 | 52.2% |
| 90834 | Psychotherapy, 45 minutes | Office | 2021 | 26 | 110 | $19,530 | $10,211 | 52.3% |
| 90792 | Psychiatric diagnostic evaluation with medical services | Office | 2021 | 15 | 15 | $3,150 | $2,469 | 78.4% |
| 90791 | Psychiatric diagnostic evaluation | Office | 2021 | 12 | 13 | $2,900 | $1,907 | 65.7% |
| 96372 | Injection beneath the skin or into muscle for therapy, diagnosis, or prevention | Office | 2021 | 12 | 99 | $5,010 | $1,334 | 26.6% |
| 90833 | Psychotherapy, 30 minutes | Office | 2020 | 114 | 863 | $123,560 | $49,886 | 40.4% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 99 | 397 | $65,010 | $32,886 | 50.6% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 103 | 459 | $58,140 | $23,926 | 41.2% |
| 90834 | Psychotherapy, 45 minutes | Office | 2020 | 21 | 63 | $11,070 | $5,040 | 45.5% |
| 90792 | Psychiatric diagnostic evaluation with medical services | Office | 2020 | 19 | 19 | $3,800 | $2,427 | 63.9% |
| 90791 | Psychiatric diagnostic evaluation | Office | 2020 | 16 | 20 | $4,400 | $2,408 | 54.7% |
| 96372 | Injection beneath the skin or into muscle for therapy, diagnosis, or prevention | Office | 2020 | 15 | 90 | $4,980 | $1,157 | 23.2% |
About Dr. Bertholet Desir, MD
Dr. Bertholet Desir, MD is a Psychiatry healthcare provider based in Brooklyn, New York. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/18/2006. The National Provider Identifier (NPI) number assigned to this provider is 1730108390.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Bertholet Desir, MD has received a total of $15,921 in payments from pharmaceutical and medical device companies, with $2,094 received in 2024. These payments were reported across 871 transactions from 21 companies. The most common payment nature is "Food and Beverage" ($15,790).
As a Medicare-enrolled provider, Desir has provided services to 1,115 Medicare beneficiaries, totaling 6,236 services with total Medicare billing of $391,388. Data is available for 4 years (2020–2023), covering 21 distinct procedure/service records.
Ad
Practice Information
- Specialty Psychiatry
- Location Brooklyn, NY
- Active Since 07/18/2006
- Last Updated 07/08/2007
- Taxonomy Code 2084P0800X
- Entity Type Individual
- NPI Number 1730108390
Products in Payments
- LATUDA (Drug) $3,008
- VRAYLAR (Drug) $2,387
- ABILIFY MAINTENA (Drug) $2,332
- REXULTI (Drug) $1,663
- CAPLYTA (Drug) $1,089
- INGREZZA (Drug) $933.28
- ARISTADA (Drug) $904.27
- INVEGA SUSTENNA (Drug) $781.87
- ABILIFY ASIMTUFII (Drug) $517.67
- AUSTEDO (Drug) $297.67
- ABILIFY MYCITE (Drug) $246.75
- Azstarys (Drug) $212.01
- UZEDY (Drug) $210.85
- HETLIOZ (Drug) $160.43
- NUEDEXTA (Drug) $139.03
- PERSERIS (Drug) $127.63
- INVEGA TRINZA (Drug) $125.00
- VYVANSE (Drug) $109.44
- SPRAVATO (Drug) $101.47
- SUBLOCADE (Drug) $100.71
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Psychiatry Doctors in Brooklyn
Dr. Mark Owens, Do, DO
Psychiatry — Payments: $502,442
Psychiatry $502,442
Dr. Nancy Abdel-Wahab, M.d, M.D
Psychiatry — Payments: $194,999
Psychiatry $194,999
Louis Belzie, Md, Phd, MD, PHD
Psychiatry — Payments: $178,082
Psychiatry $178,082
Alexander Pinkusovich, Md, MD
Psychiatry — Payments: $111,246
Psychiatry $111,246
Dr. Mark Gurtovy, M.d, M.D
Psychiatry — Payments: $31,729
Psychiatry $31,729
Thresiamma Nidhiry, Md, MD
Psychiatry — Payments: $27,833
Psychiatry $27,833